GOP Pushes Legislation to Revoke Mifepristone Approval

Senator Josh Hawley (R-Mo.) is spearheading a legislative effort to revoke the Food and Drug Administration's (FDA) approval of mifepristone, a drug used for terminating pregnancies. The proposed legislation, known as the Safeguarding Women from Chemical Abortion Act, aims to make the distribution and labeling of mifepristone a violation of the Food, Drug, and Cosmetic Act. This initiative has garnered support from three additional Republican senators: John Cornyn (Texas), Ted Budd (North Carolina), and Marsha Blackburn (Tennessee). The bill also seeks to establish a private right of action for women adversely affected by chemical abortions, allowing them to sue manufacturers for damages.

The Hill

Hawley argues that the widespread availability of mifepristone undermines the Supreme Court's 2022 decision to overturn Roe v. Wade, which was intended to empower states to regulate abortions. He contends that the ability to order mifepristone through the mail circumvents state laws designed to restrict abortions. In a letter to his colleagues, Hawley emphasized the health risks associated with the drug, stating, “No woman who has suffered from this drug has any meaningful option to recover from the two drug companies who make it, mislead about its effects—and profit from it to the tune of billions of dollars.”

The Hill

Hawley cites a study by the Ethics and Public Policy Center, which claims that 11 percent of women who took mifepristone experienced serious health effects. However, this study has faced scrutiny and fact-checks disputing its findings. In contrast, the FDA estimates the rate of serious adverse effects at approximately 0.5 percent, and other studies have corroborated this lower figure. This discrepancy highlights the ongoing debate surrounding the safety of mifepristone and the validity of the claims made by its opponents.

The Hill

Hawley has called for Republican senators to support the bill, warning that failure to act will lead to increased risks for American women. He stated, “Every pro-life group has endorsed this bill,” underscoring its significance within the anti-abortion movement. The senator has not yet discussed the possibility of a vote on the legislation with GOP leadership but insists that it is crucial for the future of the pro-life movement.

The Hill

Opponents of the bill argue that it may restrict access to safe and legal abortion services. Critics have pointed out that the claims regarding the health risks of mifepristone are not universally accepted and that the FDA's assessments provide a more favorable view of the drug's safety profile. This division reflects broader tensions within the ongoing national debate over reproductive rights and access to abortion.

The Hill

There is a notable discrepancy between the health risk statistics cited by Hawley and those provided by the FDA and other studies. While Hawley references a higher rate of serious adverse effects, the FDA's data suggests a significantly lower incidence. This conflict raises questions about the reliability of the sources being used to support the legislative push against mifepristone.

The Hill

• “Every pro-life group has endorsed this bill,” — Sen. Josh Hawley (R-Mo.)

The Hill

• “No woman who has suffered from this drug has any meaningful option to recover from the two drug companies who make it, mislead about its effects—and profit from it to the tune of billions of dollars. That should change,” — Sen. Josh Hawley (R-Mo.)

The Hill